Generated June 3, 2026 at 2:39 PM ET
· Covers June 3 trading day
· 10 of 102 ready 8-Ks selected
· AI-assisted overview
Key filings on June 3 included USA Rare Earth signing $1.6B in CHIPS Act funding for rare earth and magnet projects; Inotiv filing prepackaged Chapter 11 to reduce debt by $326M with existing equity cancelled; and Dyne Therapeutics completing enrollment of its ACHIEVE registrational cohort for DM1. Glimpse Group appointed a new CEO and chair while pivoting to Physical AI; Worthington Steel completed its €576M acquisition of Kloeckner & Co; and Axsome Therapeutics settled all SUNOSI patent litigation, deferring generic entry to 2040. DXL Group reevaluated its merger with FullBeauty; Sadot Group acquired Tradewell's Anira Consulting; Reliance Global Group regained Nasdaq compliance; and Corcept Therapeutics saw the DOJ decline to intervene in a qui tam lawsuit.
leadership
positive
materiality 0.80
June 3, 2026, 8:45 AM ET
Glimpse Group appoints Tyler Gates CEO, Admiral Swift Chair; pivots to Physical AI with SpatialCore platform
- Tyler Gates appointed President, CEO and director; William Keneally appointed CFO, effective June 1, 2026.
- Admiral Scott Swift (USN Ret.) named Chair of the Board; Major General Pete Fesler and Brian Archer join board.
- SpatialCore platform introduced – open standards interoperability layer for Physical AI, deployed with U.S. Navy.
DXLG
DESTINATION XL GROUP, INC.
M&A
negative
materiality 0.75
June 3, 2026, 7:29 AM ET
DXL Board reevaluates merger with FullBeauty, says existing terms not in stockholder interest
- Board conducted comprehensive reevaluation of merger of equals with FullBeauty (FBB Holdings I, Inc.).
- Cites challenging consumer environment and FullBeauty's indebtedness as reasons terms are not best for stockholders.
- Board engaging with FullBeauty in discussions to determine best path forward; continues to believe in industrial logic.
WS
Worthington Steel, Inc.
M&A
positive
materiality 0.80
June 3, 2026, 6:47 AM ET
Worthington Steel completes €576M acquisition of Kloeckner & Co, secures ~62% stake
- Completed voluntary takeover of Kloeckner on June 3, 2026; holds ~62% of outstanding shares.
- Total aggregate consideration for tendered shares was €576,284,588 (~52.4M shares at €11.00 each).
- Intends to launch a public delisting tender offer at €11.00 per share for remaining Kloeckner shares.
M&A
positive
materiality 0.70
June 3, 2026, 6:09 AM ET
Sadot Group completes $12M acquisition of Tradewell's Anira Consulting FZC
- Acquired 100% of Anira Consulting FZC (Tradewell) for $12M via stock and convertible note; no cash paid.
- Consideration: 135,000 common shares ($405k), 1,000 Series B Preferred ($6.595M), $5M zero-interest convertible note due 2028.
- Anira owns TradeOS CTRM platform with 11 integrated modules for commodity trading and risk management.
AXSM
Axsome Therapeutics, Inc.
litigation
positive
materiality 0.75
June 3, 2026, 9:04 AM ET
Axsome settles all SUNOSI patent litigation; generic entry deferred to 2040
- Resolved all outstanding SUNOSI patent litigation with the last first-to-file generic applicant.
- Settlement grants five companies right to sell generic SUNOSI starting September 1, 2040 (if pediatric exclusivity) or March 1, 2040.
- No other patent litigation remains for SUNOSI.
EZRA
Reliance Global Group, Inc.
regulatory
positive
materiality 0.60
June 3, 2026, 9:15 AM ET
Reliance Global Group regains Nasdaq minimum bid price compliance
- Received Nasdaq notice on June 2, 2026 that bid price was >=$1.00 for 10 consecutive days May 18-June 1.
- Previously disclosed bid price non-compliance on Dec 12, 2025; now resolved and matter closed.
- CEO Ezra Beyman cites progress on strategic initiatives and Insurtech expansion as drivers.
CORT
CORCEPT THERAPEUTICS INC
litigation
negative
materiality 0.60
June 3, 2026, 8:00 AM ET
DOJ declines to intervene in Corcept qui tam lawsuit; relator files amended complaint
- DOJ filed Notice of Election to Decline Intervention on May 19, 2026 in case U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics.
- DOJ, California Dept of Insurance, and named Plaintiff States all declined to intervene in the qui tam action.
- Relator served an amended complaint on June 2, 2026; company intends to vigorously defend.
USAR
USA Rare Earth, Inc.
other material
positive
materiality 0.90
June 3, 2026, 8:23 AM ET
USAR signs $1.6B CHIPS Act funding agreements with DOC for rare earth & magnet projects
- $277M in direct awards and $1.3B loan guarantee (15-yr, Treas+150bps) from DOC under CHIPS Act.
- Funds five projects: Round Top rare earth mine (TX), Stillwater magnet/metal expansion, two new facilities.
- Issues 16.1M shares and warrant for 17.6M shares at $17.17 to DOC; dilutive to existing holders.
other material
negative
materiality 0.85
June 3, 2026, 10:09 AM ET
Inotiv files prepackaged Chapter 11; to cut debt by $326M, cancel existing equity
- Debt reduction of approx. $326M through conversion of funded debt into reorganized company equity.
- DIP financing of $65.4M ($25M new money + $40.4M roll-up) to fund operations during Chapter 11.
- Existing common equity to be cancelled without any distribution – holders will receive nothing.
DYN
Dyne Therapeutics, Inc.
other material
positive
materiality 0.85
June 3, 2026, 7:35 AM ET
Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients
- Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.
- Potential BLA submission for U.S. Accelerated Approval in Q3 2027 using REC and MAD/LTE data.
- Potential U.S. launch of z-basivarsen in H1 2028 if FDA grants Priority Review.